Cristofanilli M, Slamon DJ, Ro J, et al. Overall survival (OS) with palbociclib plus fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC): Analyses from PALOMA-3. ESMO 2018, abstract LBA2_PR.
Video: Biomarkerdata wijzen op breed gebruik van sacituzumab govitecan bij gevorderde TNBC
dec 2020 | Borstkanker